Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

AiRuiKang (dalpiciclib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Jiangsu Hengrui Pharma

Drug class:

CDK4 inhibitor, CDK6 inhibitor

Related drugs:

‹

›

HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	dalpiciclib Sensitive: B - Late Trials dalpiciclib Sensitive : B	dalpiciclib Sensitive: B - Late Trials dalpiciclib Sensitive : B
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2
HER-2 positive	Solid Tumor	HER-2 positive	Solid Tumor	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2
CDK4 amplification	Mucosal Melanoma	CDK4 amplification	Mucosal Melanoma	dalpiciclib Sensitive: C2 – Inclusion Criteria dalpiciclib Sensitive : C2	dalpiciclib Sensitive: C2 – Inclusion Criteria dalpiciclib Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	dalpiciclib Sensitive: C2 – Inclusion Criteria dalpiciclib Sensitive : C2	dalpiciclib Sensitive: C2 – Inclusion Criteria dalpiciclib Sensitive : C2
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria pyrotinib + dalpiciclib Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	dalpiciclib + SHR 1020 Sensitive: C2 – Inclusion Criteria dalpiciclib + SHR 1020 Sensitive : C2	dalpiciclib + SHR 1020 Sensitive: C2 – Inclusion Criteria dalpiciclib + SHR 1020 Sensitive : C2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	pyrotinib + dalpiciclib Sensitive: C3 – Early Trials pyrotinib + dalpiciclib Sensitive : C3	pyrotinib + dalpiciclib Sensitive: C3 – Early Trials pyrotinib + dalpiciclib Sensitive : C3
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	pyrotinib + dalpiciclib Sensitive: C3 – Early Trials pyrotinib + dalpiciclib Sensitive : C3	pyrotinib + dalpiciclib Sensitive: C3 – Early Trials pyrotinib + dalpiciclib Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	letrozole + dalpiciclib Sensitive: C3 – Early Trials letrozole + dalpiciclib Sensitive : C3	letrozole + dalpiciclib Sensitive: C3 – Early Trials letrozole + dalpiciclib Sensitive : C3